Impact of gestrinone on the course of asymptomatic endometriosis

Eileen Thomas, E J Thomas, Thomas EJ, Cooke ID, Ian Cooke, I D Cooke
British medical journal (Clinical research ed.) · 1987 · vol. 294(6567) , pp. 272–274 · doi:10.1136/bmj.294.6567.272 · PMID:3101839 · PMC1245293 · W2065233293
RCT OA: bronze CC0 ⤵ 106 in-corpus citations
📄 Open PDF View on OpenAlex View on PubMed View at publisher
⚙ AI-generated summary by gemini-2.5-flash-lite, 2026-06-09 ⓘ

Gestrinone was found to be an effective treatment for asymptomatic endometriosis, significantly improving disease symptoms compared to placebo.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

A new drug, gestrinone, was subjected to the first double blind, randomised placebo controlled trial of any treatment of endometriosis. The disease deteriorated in eight (47%) of the 17 patients prescribed placebo (95% confidence limits 23% and 71%) compared with none of the 18 patients prescribed gestrinone (p = 0.002). There was a difference in elimination of the endometriosis in the gestrinone group compared with placebo but this was not statistically significant (p = 0.057). There was a significant difference in improvement of the disease in the gestrinone group compared with placebo (p = 0.004), confirming that gestrinone is an effective treatment of endometriosis. Endometriosis deteriorates in at least 23% of patients; as it is impossible to predict in whom this will happen, treatment appears to be warranted in all cases.

My notes (saved in your browser only)

Condition tags

endometriosis

MeSH descriptors

Endometriosis Gestrinone Norpregnatrienes Adult Adult Clinical Trials as Topic Clinical Trials as Topic Double-Blind Method Double-Blind Method Endometriosis Endometriosis Female Female Gestrinone Gestrinone Humans Humans Norpregnatrienes Norpregnatrienes Random Allocation

Citation neighborhood (2-hop)

Papers in the corpus that this work cites (lower rings, blue) and that cite this one (upper rings, green). Dot size scales with the paper's in-corpus citation count — bigger dot = more influential within the endo/adeno field. Click a dot to open that paper. Outer rings show 2-hop neighbours — papers reached through the immediate citers/citees. [ collapse to 1-hop ]

References (14)

Cited by (50)

Source provenance

europepmc
last seen: 2026-10-16T06:09:50.462052+00:00
openalex
last seen: 2026-06-10T17:14:06.276822+00:00
pubmed
last seen: 2026-10-08T21:24:24.182414+00:00
License: CC0 · commercial use OK